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The serpin plasminogen activator inhibitor-1 (PAI-1) is a crucial regulator in fibrinolysis and tissue remodeling. PAI-1 has
been associated with several pathological conditions and is a
validated prognostic marker in human cancers. However, structural information about the native inhibitory form of PAI-1 has
been elusive because of its inherent conformational instability
and rapid conversion to a latent, inactive structure. Here we
report the crystal structure of PAI-1 W175F at 2.3 Å resolution
as the first model of the metastable native molecule. Structural
comparison with a quadruple mutant (14-1B) previously used as
representative of the active state uncovered key differences. The
most striking differences occur near the region that houses three
of the four mutations in the 14-1B PAI-1 structure. Prominent
changes are localized within a loop connecting ␤-strand 3A with
the F helix, in which a previously observed 310-helix is absent in
the new structure. Notably these structural changes are found
near the binding site for the cofactor vitronectin. Because vitronectin is the only known physiological regulator of PAI-1 that
slows down the latency conversion, the structure of this region is
important. Furthermore, the previously identified chloridebinding site close to the F-helix is absent from the present structure and likely to be artifactual, because of its dependence on the
14-1B mutations. Instead we found a different chlorine-binding
site that is likely to be present in wild type PAI-1 and that more
satisfactorily accounts for the chlorine stabilizing effect on
PAI-1.

Plasminogen activator inhibitor-1 (PAI-1)4 is a specific and
fast-acting inhibitor of each of the two plasminogen activators,
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tissue type (tPA) and urokinase type plasminogen activator and
thus an inhibitor of plasmin-mediated fibrinolysis and tissue
remodeling. Since its discovery in the mid-1980s, this member
of the serpin family has been intensely studied to achieve an
in-depth understanding of its physiological and pathophysiological functions (for a review see Ref. 1). PAI-1 has been
directly implicated in cardiovascular diseases and cancer and is
a potential therapeutic target (for reviews see Refs. 2 and 3). In
addition to the target proteases, PAI-1 also binds to endocytosis
receptors of the low density lipoprotein receptor family and the
extracellular matrix glycoprotein vitronectin (for a review, see
Ref. 1). To better understand these molecular interactions,
many loss-of-function or loss-of-interaction mutants have
been constructed (4).
Central to the protease inhibition mechanism is the 20-residue surface-exposed loop called the reactive center loop (RCL)
that initially interacts with the target serine protease in the
same way as a substrate. Following the initial protease cleavage,
the N-terminal part of the RCL inserts as strand 4 in ␤-sheet A
(s4A), the central sheet in PAI-1, translocating the covalently
linked protease to the opposite pole of the serpin and thereby
trapping it in an inactive covalent complex. The insertion of the
RCL into ␤-sheet A is believed to release energy needed to drive
the inhibitory mechanism, converting the serpin into the thermodynamically most stable form (5, 6). Under certain conditions, PAI-1 exhibits “substrate behavior,” during which the
active protease is prematurely released prior to RCL insertion,
leaving the serpin in an inactive protease-cleaved form (for
reviews, see Refs. 1 and 4).
PAI-1 shares a unique functional feature among less than a
handful of serpins in its ability to spontaneously insert the RCL
into ␤-sheet A without prior cleavage with a half-life of 1–2 h at
37 °C, resulting in a thermodynamically more stable and noninhibitory state, termed the latent form (7). The physiological
function of latency transition is still uncertain but may serve as
a protection against long term anti-fibrinolytic actions of
PAI-1. Latency transition adds an experimental challenge for
time extensive in vitro and in vivo assays on PAI-1 or when
growing protein crystals.
In 1995, a quadruply mutated (N150H, K154T, Q319L, and
M354I) PAI-1 termed 14-1B was isolated by random mutagenesis screens. The conversion of 14-1B to the latent state at 37 °C
was delayed by more than 70-fold. In addition, 14-1B exhibits a
large increase in thermodynamic stability, manifested by a
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10 °C increase in the denaturation temperature (8). The first
x-ray crystal structure of active PAI-1 was determined with
14-1B at a resolution of 3 Å (9). The structure featured the same
overall fold as other inhibitory serpins (for a review, see Ref. 10).
Higher resolution structures of active 14-1B have since been
determined (see supplemental Table S1), with resolutions of 2.7
(11) and 2.4 Å (12), respectively. Because 14-1B retained inhibitory activity toward the target proteases, the x-ray crystal
structure analysis of 14-1B has provided the basis for many
biochemical investigations of active PAI-1, including the mapping of sites for molecular interactions and interpreting functional effects caused by single or multiple mutations in PAI-1
(4). However, accumulating evidence has raised questions
about the validity of using 14-1B as a valid representative of the
wild type protein (13–16). As examples, 14-1B was observed to
differ from native PAI-1 when analyzing the binding of a set of
conformational specific antibodies (14) and when studying the
ability of PAI-1 to induce multimerization of its cofactor vitronectin (16).
In a study designed to dissect the contributions to the intrinsic fluorescence from each of the four Trp residues in human
PAI-1, Trp175, which is highly conserved among serpins, was
substituted with a Phe. In addition to a small increase in substrate behavior when reacting with tPA and an only 3.5-fold
delayed latency transition (t1⁄2 ⫽ ⬃7 h, 37 °C), W175F behaved
similarly to wild type PAI-1 with regard to all tested biochemical functions (17). The mutated residue is centered in the
“breach” region, where ␤-sheet A opens to allow the insertion of
the first residue of the RCL. Residue 175 was shown to be
important for the regulation of the rate of insertion of the first
few residues of the RCL (17).
Here we report the crystal structure of PAI-1 W175F at 2.3 Å
resolution. We were able to identify a previously unknown
chloride site that leads to a revised hypothesis of how elevated
salt concentrations stabilize the inhibitory activity of PAI-1.
Furthermore, two novel binding sites for Zn2⫹ were identified
that likely contribute to the reported affinity of PAI-1 for divalent metal ions. We demonstrate that W175F PAI-1 has a thermodynamic stability comparable with that of active wild type
PAI-1. In accordance with this, the structural analysis provides
evidence that a single substitution does not impose significant
structural deviations from the wild type conformation. Comparison with the current structural model of active PAI-1
reveals significant structural differences with biochemical
implications. We believe that our new structure represents a
correct model for the metastable active form of PAI-1, thus
providing some missing key information that enhances the
structural characterization of the active form. Our observations
also provide evidence that the thermodynamic stability of serpins is not the only determinant of the rate of RCL insertion.

EXPERIMENTAL PROCEDURES
W175F PAI-1 Protein Expression—A pET-24d expression
vector (Novagen) containing the human PAI-1 full-length DNA
sequence (from the N-terminal 1VHHPPS6) without any tags
was a kind gift from Grant E. Blouse. The W175F substitution
was created by site-directed mutagenesis according to the
QuikChange protocol (Stratagene). Rosetta2 BL21 (DE3) pLysS
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cells were transformed with the vector and grown at 30 °C while
agitating in LB medium supplemented with 50 g/ml kanamycin and 34 g/ml chloramphenicol until an optical density at
600 nm of ⬃1 was reached. The temperature was reduced to
15 °C, and the cell culture was allowed to cool for 2 h before
protein expression was induced by adding isopropyl ␤-D-1thiogalactopyranoside to a final concentration of 1 mM. After
an overnight incubation at 15 °C, the cells were harvested by
centrifugation and stored in pellet form at ⫺80 °C until protein
purification.
Purification of W175F PAI-1 Protein—Cell pellets were
resuspended in 50 mM NaH2PO4, pH 6.5, 1 mM EDTA, and 10
mg of Sigma protease inhibitor mixture P8465 was added per
gram of pellet. The cells were lysed by sonication on ice, and the
supernatant containing soluble W175F PAI-1 protein was
cleared by centrifugation. The following was all performed at
4 °C. The supernatant was loaded onto a SP Sepharose FF column and washed extensively with 50 mM NaH2PO4, pH 6.5, 80
mM (NH4)2SO4, and 1 mM EDTA, and bound protein was eluted
with a linear gradient of 80 –500 mM (NH4)2SO4. PAI-1-containing fractions (high concentrations of (NH4)2SO4) were
pooled and dialyzed overnight against 50 mM NaH2PO4, pH 7.0,
500 mM NaCl, and 20 mM imidazole and subsequently loaded
onto a chelating Sepharose FF column charged with nickel. The
column was then washed and eluted with a 20 –120 mM imidazole gradient. Fractions were captured into NaH2PO4, pH
6.25, NaCl, and EDTA (final [EDTA] ⫽ 5 mM). The PAI-1 containing fractions were pooled, concentrated, and loaded onto a
2.5 ⫻ 115 cm high resolution Sephacryl S-100 column extensively equilibrated in 50 mM NaH2PO4, pH 6.25, 300 mM NaCl,
and 1 mM EDTA. W175F PAI-1 eluted as a single peak, the
fractions of which were pooled, concentrated, and stored at
⫺80 °C. Protein purity better than 95% was confirmed by Coomassie Brilliant Blue-stained reducing SDS-PAGE, and the
identity was confirmed by Western blot and MALDI-MS. Protein concentration was determined by measuring the optical
density at 280 nm using ⑀280 ⫽ 0.70 ml䡠mg⫺1䡠cm⫺1 and a
molecular weight of 42,730 (both calculated using the ProtParam tool at the ExPASy Bioinformatics Resource Portal). The
strategy of employing a low temperature during expressing
ensures that only an insignificant amount of latent W175F
PAI-1 protein is present in the preparations.
PAI-1 Stability Assay—The inhibitory activity of the PAI-1
preparation was tested by titration with tc-tPA. The relative
amount of functional tPA was determined using a chromogenic
assay by the addition of 1 mM Spectrozyme tPA (American
Diagnostica Inc). The release of free p-nitroaniline upon cleavage of the substrate by tPA was monitored at 405 nM. Typical
PAI-1 preparations were ⱖ85% active. The rate of conversion
of PAI-1 to the latent form was determined essentially as
described previously (14). A sample of 100 nM PAI-1 was equilibrated in 20 mM HEPES, pH 7.4, containing 1% BSA at 37 °C.
Sodium halide solutions (NaCl, NaF, or NaBr) were added to a
final concentration of either 150 mM or 1.0 M. Over time, aliquots were mixed with active tPA at a final concentration of 50
nM PAI-1 and 60 nM tPA. Relative PAI-1 activity was normalized and fit to a single exponential to determine klat, the rate
VOLUME 286 • NUMBER 34 • AUGUST 26, 2011
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constant for conversion to the latent form. The data are the
averages of three separate experiments.
Thermal Stability Monitored by CD Spectroscopy and Differential Scanning Calorimetry—Thermal denaturation of PAI-1
by CD spectroscopy was performed on a JASCO-810 circular
dichroism system, equipped with Peltier temperature-controlled cuvette holder. The change in CD signal was followed at
222 nm while heating a 1-cm cuvette containing 10 g/ml
PAI-1 in 0.1 °C steps from 35–75 °C at a ramp speed of 50 °C/h
under mild agitation. Denaturation curves were an average of
three independent experiments, corrected for buffer scan and
normalized to 1. Melting point temperatures (Tm) were
obtained from the inflection point of the sigmoid curves by
nonlinear fit of the data as described (18). Native and 14-1B
Escherichia coli PAI-1, used for comparison, was prepared in a
similar way as described above. Latent PAI-1 was prepared by
incubating the native PAI-1 sample at 37 °C for ⬎24 h prior to
the CD experiment. All of the samples were prepared in 50 mM
NaH2PO4, pH 6.6. Thermal denaturation of PAI-1 by differential scanning calorimeter (DSC) was performed on a MicroCal
VP-DSC. The DSC curves were obtained by heating the sample
and reference cell from 20 to 90 °C at a rate of 90 °C/h. Protein
samples were prepared by dialysis against 50 mM NaH2PO4, pH
6.6, supplemented with 500 mM NaCl to prevent protein precipitation at the PAI-1 concentrations of ⬃0.8 mg/ml required
for the DSC measurement.
Crystallization of W175F PAI-1—Protein sample and crystallization conditions from the previous crystallization study of
14-1B PAI-1 (12) were chosen as the starting point for crystallization of W175F PAI-1. In parallel crystallization trials with
the available sparse matrix screens, kits from Hampton were
performed; these screens, however, did not yield any crystals of
diffraction quality. W175F PAI-1 protein sample was bufferexchanged into crystallization buffer (20 mM MES, pH 6.1, 500
mM NaCl) to a final concentration of 11 mg/ml. Crystals
appeared within 2 weeks at 18 °C by hanging drop vapor diffusion against a reservoir of 0.5 ml 0.5–3.0 M NaCl. The data were
collected at 100 K.
Cryoprotection—Crystals were cryoprotected either by quick
(10 –30 s) soak in a drop of well solution supplemented with
25% ethylene glycol supplemented with 0.5 M NaCl or by adding
ethylene glycol directly to the drop containing crystals. The
later procedure was done by first adding ethylene glycol to a
concentration of ⬃12.5% following 20 min of incubation before
further addition to a concentration of ⬃19% allowing additional ⬃2-h incubation. Crystals were mounted in 0.05–
0.2-mm nylon loops (Hampton) and snap-frozen in liquid
nitrogen or directly in the nitrogen cryostream at the beamline.
Diffraction Data Collection and Processing—A native data set
to 2.3 Å resolution was collected at 100 K on the end station
X06SA at the Swiss Light Source (SLS) in Villingen at a wavelength of 1.001 Å (data set 1). A long wavelength data set at the
zinc edge was carried out at 1.280 Å on the end station X12 at
EMBL Hamburg (data set 2). On-site software was used to validate the crystal diffraction quality as well as preliminary indexing of data from the individual crystals. The data set 1 and 2
were indexed, integrated, and scaled in space group P21 using
the XDS program package (19) (see Table 1). The final structure
AUGUST 26, 2011 • VOLUME 286 • NUMBER 34

factor files were prepared using XDSCONV (XDS program
package) and subroutines in the CCP4 suite (20).
Structure Determination and Refinement—The initial phases
were obtained by molecular replacement with (PDB code
1DVM) as search model, refinement, and validation with programs within the PHENIX program package (21). Model building was performed in COOT (22). Structure figures were prepared using the PyMOL molecular graphics system (version
1.2r3pre).

RESULTS
W175F Has Wild Type Thermodynamic Stability—It was
previously shown that the 14-1B PAI-1 variant exhibited a more
than 70-fold increased functional stability as well as a large
increase in thermal stability, both indicative of a structure decisively different from that of wild type PAI-1. To investigate the
effects of the more modest side chain alteration in the W175F
variant, its thermal stability was determined by CD spectroscopy. The denaturing temperature for W175F was determined
to be 50.8 ⫾ 0.4 °C (Fig. 1A and supplemental Fig. S1), indistinguishable from the 50.2 ⫾ 0.3 °C of active wild type PAI-1 (p ⫽
0.1062, Students’ t test). Both values were significantly lower
than those observed for 14-1B (59.7 ⫾ 0.3 °C, p ⬍ 0.0001, Students’ t test) and latent wild type (68.1 ⫾ 0.4 °C, p ⬍ 0.0001).
Importantly, the melting point temperatures of active and
latent wild type PAI-1 as well as of active 14-1B agreed well with
previously published data (8, 18).
To confirm the observed melting point temperatures (Tm) of
the three PAI-1 samples by an independent method, we used
DSC. Although it was necessary to increase the NaCl concentration to 500 mM to maintain the elevated protein concentration needed for a DSC experiment (⬃0.8 mg/ml), the observed
melting point temperatures were comparable with those determined by CD. The denaturation temperature of W175F was
indistinguishable from active wild type PAI-1 with peaks centered at ⬃52 °C (Fig. 1B). Consistent with the CD measurements, 14-1B denatured in the calorimeter at a temperature
⬎12 degrees higher than both wild type and W175F PAI-1, with
a Tm value between 65 and 67 °C.
During all thermal melting experiments using either CD or
DSC, denaturation of PAI-1 was accompanied by bulk precipitation of the sample protein. For the DSC experiments with
14-1B PAI-1, this irreversible unfolding skewed the shape of the
transition point peak and the postdenaturation baseline. This
perturbed peak shape prevented the determination of a precise
Tm. This protein precipitation above the melting temperatures
precluded a full thermodynamic analysis of the unfolding/folding process. Nonetheless, these striking thermal stability data
prompted us to pursue three-dimensional structure determination on W175F as a model for the metastable active structure of
PAI-1.
Initial Structural Observations—The combination of a
slightly delayed rate of latency transition rate and an optimized
expression and purification protocol helped to maintain the
active conformation of W175F during preparation and crystallization. Protein crystals grew readily from conditions similar to
those previously reported for 14-1B PAI-1 (12). Two data sets
were used for refinement (Table 1). Data set 1 at 2.3 Å resoluJOURNAL OF BIOLOGICAL CHEMISTRY
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TABLE 1
Data collection and refinement statistics
Protein Data Bank code

3Q02

3Q03

Data collection
Synchrotron
Beamline
Wavelength (Å)
Resolution range (Å)a
Space group
Unit cell dimensions
a, b, c (Å)
␣, ␤, ␥ (°)
Mosaicity (°)
Unique reflectionsa
Completeness (%)a
Redundancy a
Rmeas (%)a,b
I / I a
Wilson B-factor
Refinement
Resolution range (Å)a
Rwork (%)c
Rfree (%)d
Atomic model
Protein atoms
Ions
Cl⫺
Zn2⫹
Other ligand
Water molecules
Root mean square deviationse
Bond lengths (Å)
Bond angles (°)
Ramachandran favored
Ramachandran allowed
Ramachandran outliers

Data set 1
SLS Villingen
PX06SA
1.00
30–2.29 (2.39–2.3)
P21

Data set 2
EMBL Hamburg
X12
1.28
30–2.6 (2.75–2.64)
P21

77.44, 67.17, 90.36
90.0, 98.5, 90.0
0.14
40,531 (4366)
98.7 (97.9)
4.7 (4.6)
5.2 (70.6)
17.61 (2.10)
57.5

76.68, 67.16, 91.16
90.0, 100.5, 90.0
0.17
52,134 (6049)
99.1 (99.6)
3.2 (3.2)
9.1 (58.4)
11.19 (2.03)
48.4

20–2.3 (2.39–2.3)
19. 1
23.8

20–2.64 (2.68–2.64)
17.2
22.5

5770

5791

2
2
1
145

2
2

0.029
2.525
96.77%
3.09%
0.14%

0.006
1.186
96.37%
3.63%
0.00%

247

a

The values in parentheses indicate the shell of highest resolution.
1
Rmeas ⫽ 兺hkl (N/(N ⫺ 1)) ⁄2 兺i兩Ii,hkl ⫺ ⬍Ihkl⬎兩/ 兺hkl 兺I兩Ii,hkl兩.
c
Rwork ⫽ 兺hkl兩Fobs ⫺ Fcalc兩/兺hkl兩Fobs兩.
d
Rfree is calculated like Rwork but from 5% (random subset) of the reflections excluded from the refinement.
e
From ideal values.
b

FIGURE 1. Thermal denaturation experiments by CD and DSC. A, CD thermal denaturation profiles of the indicated PAI-1 variants are represented by
the curves from fits using equation 1 to the raw data for active W175F (thick
solid line), active 14-1B (broken line), or active (thin line) and latent (dotted line)
wild type PAI-1. The data correspond to the normalized change in CD signal of
the respective samples as a function of temperature. Denaturation temperatures, averaged from three independent measurements, are given by the
labels on the corresponding curves. B, DSC curves of active W175F (thick solid
line), active wild type (thin line), and active 14-1B PAI-1 (broken line). The melting point temperature of the protein corresponding to the midpoint of the
thermal transition peak in each individual DSC curve is given as a label to the
corresponding peak.

tion formed the basis for the main structural analysis, whereas
data set 2 at 2.6 Å resolution was collected at a low energy
wavelength above the Zn2⫹ and Cu2⫹ edge ( ⫽ 1.5) to allow
reliable identification of atoms with anomalous scattering in
the difference Fourier map. We attribute the higher refinement
statistics for data set 1 (Rwork and Rfree) to the accumulation of
radiation damage introduced during data collection at the
Swiss light source, because of the higher x-ray brilliance. It
should be noted that only a few crystals diffracted to 2.3 Å.
These crystals were small in size (⬃40 ⫻ 40 ⫻ 40 m), leaving
the crystal completely bathed in x-rays throughout the entire
exposure, resulting in increased radiation damage as compared
with crystals larger than the x-ray beam. Larger crystals will in
principal include nonradiated crystal for the initial 180 degrees
of exposure. It is noteworthy that this crystal form crystallizes
in a different space group and with different unit cell parameters as compared with the previous 14-1B crystals (see supple-
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FIGURE 2. Structure of active W175F PAI-1. The results of the x-ray crystallography are shown in a front and back cartoon representation oriented
with the central ␤-sheet A in the plane of the paper and the RCL toward
the top. The structure is overlaid with the 14-1B structure shown in gray
cartoon (PDB code 1DVM) by alignment using statistical alignment algorithms in RAPIDO. Invariant regions are colored in blue and regions deviating statistically color-scaled yellow, orange, or red according to increasing deviations between the structures. The chloride-binding sites in the
W175F and 14-1B structures are highlighted by green or gray spheres,
respectively. Secondary structure elements (␣-helix (h) and ␤-sheet (s)) are
labeled, and the specific numbering of strands 1–3, 5, and 6 of sA is shown.
The RCL is sketched with a hypothetical dashed black line replacing the
missing main chain in the W175F structure.

VOLUME 286 • NUMBER 34 • AUGUST 26, 2011
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FIGURE 3. Cartoon drawing of the crystal asymmetry unit containing two
molecules of W175F chain A and B. The positions of Cl⫺ and Zn2⫹ ions are
marked with yellow and blue spheres, respectively. The electron density of the
two Zn2⫹ ions is contoured at 3.0 sigma (red mesh) in the difference Fourier
map. Residues in coordinating distance to the Zn2⫹ ions are highlighted as
sticks and labeled by arrows and text.

mental Table 1). The final model (Fig. 2) is more than 95%
complete and shares the common overall fold of an active serpin observed with other inhibitory members of the family. As
expected, the electron density of the solvent-exposed flexible
RCL (Ser331–Pro349) is missing and reflects the ability of the
RCL to adopt different conformations suitable for the interaction with target proteases (10). Strong peaks in the difference
map of data set 2 clearly identify two Zn2⫹ sites bridging the
two PAI-1 molecules in the asymmetric unit. The strongest site
is coordinated by the two N-terminal histidine residues 2 and 3
(Fig. 3). Furthermore, the difference maps reveal the localization of a previously unknown halide-binding site (Figs. 2 and 4).
Chloride-binding Site in the Gate Region—From the anomalous diffraction data, it was evident that a strong, well defined
chloride-binding site was located in the center of the functionally important “gate” region (Fig. 2), the region through which
the unbroken main chain extracted from ␤-sheet C must pass to
allow the complete insertion of the RCL in ␤-sheet A during
latency transition. From a mechanistic point of view, the chloride atom could act as a gatekeeper by bridging several structural elements situated between the s3C/s4C loop and the loop

FIGURE 4. Top panel, close-up view of the chloride-binding site centered in the gate region. Side chains within 5 Å of the Cl⫺ ion are shown as sticks with
corresponding residue labels. Alignments are shown with 14-1B structure (gray, PDB code 1DVM, A) and latent wild type PAI-1 (gray, PDB code 1LJ5, B).
The electron density of the chloride is contoured at 3.0 sigma (red mesh) in the difference Fourier map. Arrows mark position changes of highlighted side
chains during latency transition. The loop strand extracted from ␤-sheet C during latency transition with the pivotal point at Pro357 extending to the
bottom right of the figure is marked in the latent structure with magenta. The Arg356 side chain is missing in the 14-1B structure. Bottom panel, a close-up
representation of the mutated position 175 in the upper part of the breach region. Neighboring side chains within 5 Å of Phe175 are depicted as sticks
with corresponding residue labels. Statistically calculated alignments in RAPIDO are shown with 14-1B structure (gray, PDB code 1DVM, C) and latent
wild type PAI-1 (gray, PDB code 1LJ5, D). Arrows mark position changes of highlighted side chains during latency transition.

AUGUST 26, 2011 • VOLUME 286 • NUMBER 34
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FIGURE 5. Close-up view of the hF loop region consisting of hF and the loop Thr144–Arg162 connecting hF with s3A. All of the figures contain the W175F
structure in a red cartoon presentation with the connecting loop highlighted in yellow. A, the residues in loop Thr144–Arg162 are emphasized in stick presentation with the corresponding electron density at a sigma level of 1.0 in the 2Fo ⫺ Fc map. B, overlaid with the active 14-1B (gray, PDB code 1DVM). C, overlaid
with the latent PAI-1 (gray, PDB code 1LJ5). All of the alignments are by direct alignment of the hF loop regions. ␣-hF and strands 1– 6 of ␤-sheet A (sA) are
labeled.

connecting s3B with hG, blocking the gate and thereby delaying
latency transition (Fig. 4).
Salt Stabilization Occurs with Wild Type and W175F PAI-1—
To support that a functional chloride site is found in both wild
type and W175F PAI-1, we evaluated the stabilizing effect of
high NaCl concentrations and showed this feature to be conserved between the two forms of PAI-1. This was demonstrated
using standard latency transition assays performed at 37 °C
(supplemental Fig. S2). The observed half-lives for the decay of
inhibitory activity in the presence of 150 mM NaCl were ⬃49
and ⬃199 min for wild type and W175F PAI-1, respectively,
consistent with observed variations of measured half-lives
depending on buffer composition and experimental conditions
(data not shown). Furthermore, both wild type and W175F
PAI-1 exhibit a marked stabilization upon increasing the NaCl
concentration to 1.0 M. A less than 10% drop in protease inhibition was observed over a 7-h time frame, yielding rough estimates of half-lives well above 30 h (⬎1800 min).
Stabilization Is Specific to Chloride Ions—To test the specificity of halide binding in the observed chloride-binding site, we
performed similar kinetic stabilization studies using NaF and
NaBr. In the presence of a 150 mM concentration of either NaF
or NaBr, the inhibitory half-lives of wild type and W175F PAI-1
were similar to those measured in 150 mM NaCl (supplemental
Table S2). In contrast to the dramatic stabilization observed
with 1.0 M sodium chloride, the effects of the other halide
salts are not as pronounced. A concentration of 1.0 M NaBr
resulted in a modest stabilization, whereas a 1.0 M concentration of NaF yielded an intermediate level of stabilization
of both PAI-1 variants. The stabilizing effect of NaF was only
1.9-fold for W175F PAI-1 and ⬃4-fold for WT PAI-1 in contrast to the ⬎10- and ⬎36-fold effect of NaCl in the same
assay (supplemental Table S2).
Mapping Structural Differences by Statistical Approaches— To
perform reliable structural comparisons between active and
inactive PAI-1 conformations, we used the flexible alignment
program RAPIDO (23). RAPIDO takes advantage of a genetic
algorithm developed to create accurate comparisons of structures by taking the difference in statistical error into account.
This is of utmost importance when comparing structures of
different resolution and data quality (24), factors that directly
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affect the quality and resulting interpretations drawn from such
alignments. Alignment of W175F with active 14-1B (PDB code
1DVM) (12) (Fig. 2) identified numerous structural differences.
The Most Prominent Structural Difference Is in the Helix F
Loop Region—An important difference is observed in the region
containing hF and the adjacent loop connecting hF to s3A,
termed the hF loop region. The markedly increased functional
as well as structural stability of 14-1B has been credited to clustering of three (N150H, K154T, and Q319L) of the four mutations in and below the loop connecting ␣-helix F (hF) with
strand 3 in ␤-sheet A (s3A) (9). The clustering of these mutations induces a 310-like helix observed in all but one available
structure of active 14-1B (Fig. 5B). The one interesting exception is observed when 14-1B is complexed with the N-terminal
domain of vitronectin. In this complex the hF loop region
reverts to a conformation close to that observed in W175F (25),
in which the 310 helix was not observed.
Widespread Conformational Differences—The differences
observed in the alignment of W175F and 14-1B PAI-1 reveal the
consequences of mutations in 14-1B and extensive relayed conformational changes (Fig. 2). One consequence of these mutations is a slight clockwise twist of hF that transmits a further
structural change through movement of s1A. Moreover, there
is a direct contact between the top part of hF and the loop
between hD and s2A termed the “W86 loop,” i.e. a salt bridge
between Lys145 and Asp90. This interaction is not observed in
the W175F structure. These changes together perturb the
conformation of the W86 loop and the position of hD in
14-1B as compared with the other structures. The combined
effects of the conformational change of the W86 loop and the
rearrangement of hD confer a noteworthy change in ␤-sheet
A in which s2A and s3A are observed to be markedly shorter
in W175F compared with 14-1B. Finally, a large conformational change is found on the “back” of the structure (Fig. 2),
where hH and hG both shift toward the observed chloridebinding site. Interestingly, the mobility of these two helices
suggests an intramolecular communication between the gate
region and s2C, the position from which s1C adjacent to the
RCL detaches before passing through the gate during latency
transition.
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DISCUSSION
As a member of the serpin superfamily, PAI-1 shares common structural features with others in the family. Specifically,
the serpins are comprised of a core fold containing three
␤-sheets and several ␣-helices, with the RCL protruding from
the core and accessible to target proteases. A unique feature of
serpins is that their native forms are “metastable” because the
exposed RCL is not in its most stable conformation. The mobility of the RCL is the feature that guides the inhibitory activity of
serpins, and the RCL inserts readily into the central ␤-sheet
upon cleavage by proteases and formation of a covalent acylintermediate. The driving force for this conformational change
is thermodynamic, yielding a more stable and more extensive
central ␤-sheet.
W175F PAI-1 Offers a Model of Native PAI-1—With PAI-1,
this insertion of the RCL into the central ␤-sheet occurs readily,
even without an interaction with target proteases, yielding a
latent conformation that is inactive. Although serpins are all
characterized by the metastable nature of the active conformation, the latency conversion for most is quite slow. In contrast,
the conversion to the latent conformation occurs readily with
PAI-1, with a half-life of only ⬃1 h at 37 °C. This facile relaxation of PAI-1 to the latent form has hampered structural determination of the metastable active protein. The main force driving the structural rearrangement of PAI-1 during protease
inhibition and latency transition is the large thermodynamic
energy difference between the active conformation and the
more stable RCL-inserted forms. Here we confirm published
data showing that the functional stabilization of 14-1B PAI-1 is
also accompanied by a large increase in thermodynamic stability (Fig. 1), whereas W175F PAI-1 has thermodynamic stability
comparable with that of wild type PAI-1. The determination of
the x-ray crystallographic structure of W175F PAI-1 thus provides a more relevant structure for the metastable active form.
Structural Changes Are Apparent near the Vitronectin-binding Site in the Flexible Joint Region—Several structural features
of W175F differ from the well characterized 14-1B form, which
is dramatically stabilized so that it has lost most of its metastable character. A binding partner for PAI-1 that exists in high
concentrations in plasma and tissues is vitronectin. Association
of PAI-1 with vitronectin stabilizes the active conformation and
significantly slows the latency transition. The complex of the
N-terminal somatomedin B domain from vitronectin and
PAI-1 has been determined (25), revealing a binding site in
PAI-1 that is known as the flexible joint region in the vicinity of
␤-strands 1A, 2A, and 3A and the nearby helices D and E. The
previously determined structure for the constitutively active
14-1B form of PAI-1, which has been the prior reference structure for the “active” form of PAI-1, contains four mutations,
three of which are in the vicinity of this flexible joint region.
Strikingly, the most notable structural differences comparing
the W175F and 14-1B structures are proximal to this region.
Notably, the loop connecting hF with strand 3A spanning the
flexible joint region is missing a 310-helix that is observed in the
14-1B structure. Such a difference near the binding region for
the key regulatory protein vitronectin makes the W175F PAI-1
AUGUST 26, 2011 • VOLUME 286 • NUMBER 34

structure preferred for ongoing studies on vitronectin-PAI-1
interactions.
The Helix F Loop Region Is Likely to Move as an Independent
Domain—The conformation of the hF loop region in W175F
closely mimics the conformation observed in the latent (9) (Fig.
5C) and the cleaved (26) (not shown) structures of PAI-1. The
fact that the fold in the hF loop region is invariant between the
active W175F and the latent structure indicates that this region
behaves as an independent unit that remains unaffected by the
major structural rearrangements in the remainder of the PAI-1
molecule during the insertion of the additional ␤-strand into
sheet A (Fig. 5C). This observation supports the idea that the hF
loop region moves as a rigid unit to allow space for the insertion
of the RCL (27).
Other Structural Differences Distinguish the Metastable and
Constitutively Active Structures—In the work described by
Blouse et al. (17), in which W175F PAI-1 was generated, the
exchange to phenylalanine was hypothesized to slow early preinsertion of the RCL prior to latency transition. In support of
the importance of the area around position 175 is the model
that includes an intermediate form of active wild type PAI-1
with a partially inserted RCL, a form termed the “prelatent”
form (13, 14, 28, 29). Although no direct structural evidence
exists for this prelatent form of PAI-1, it is thought to resemble
what is observed for native antithrombin (30) in which the first
few N-terminal residues of the RCL are inserted into a partially
open ␤-sheet A, with the conformation of the breach region
resembling what was observed for the structures of both the
latent (PDB code 1LJ5) and cleaved (PDB code 3CVM) PAI-1.
Our new structure for W175F PAI-1 reveals shorter lengths
observed for s3A and s2A that could facilitate the early stages of
preinsertion. Although this is not direct proof, the structure
would favor the ease of preinsertion and would thereby speed
up RCL insertion, consistent with the relative fast decay of
inhibitory activity of both wild type and W175F PAI-1 as compared with the slow transition of 14-1B. Furthermore, evidence
from other serpins indicates the area spanning the top of s2A,
s3A, and the connection to hD to be an important regulatory
element by which cofactor binding to hD and hE influences the
conformation of the RCL and thereby the reactivity of the serpins toward target proteases (30, 31). Our structural analysis
also provides an explanation for why a conformationally sensitive antibody that recognizes the W86 loop preferentially binds
to wild type active PAI-1 over active 14-1B (14). This W86 loop
is significantly different between our structure and the structure of 14-1B (data not shown). Specifically, the bulky side chain
of W86 protrudes into the solvent in our structure, whereas it
points inwards and is buried inside the structure of 14-1B. From
these comparisons, we conclude that the four point mutations
in 14-1B result in widespread conformational differences (Fig.
1) that apparently lead to a general higher conformational rigidity of 14-1B.
The region around the single substituted residue Phe175
reveals no significant changes in the backbone conformation
when compared with 14-1B (PDB code 1DVN) and a relatively
modest shift when compared with the latent conformation
(PDB code 1DVM) of PAI-1. Nonetheless, the side chain at
position 175 occupies the same site, which presumably exhibits
JOURNAL OF BIOLOGICAL CHEMISTRY
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complementarity and high affinity for aromatic side chains (Fig.
4, C and D). The mechanism that results in the mere 3.6-fold
slower latency transition in the W175F mutant thus appears to
result from local effects caused by the substitution of the Trp
side chain by Phe, which increases the activation energy for
RCL insertion rather than inducing global structural changes
and stabilization as observed for 14-1B. Taken together, the
differences between the W175F and 14-1B PAI-1 structures
harbored in key regions for vitronectin binding and affecting
the length of S2A and S3A, with minimal changes at the site of
the mutation, indicate that the W175F structure represents a
new unbiased model for the native active fold of the PAI-1
molecule.
The Chloride-binding Site in the Gate Region Accounts for the
Stabilizing Effect of Salt—The hypothesis that the salt-dependent stabilization of PAI-1 activity is caused by a specifically
bound chloride atom was originally proposed by Stout et al.
(12). Although our new data support this hypothesis, the originally proposed location of the binding site in the 14-1B structure close to the hF loop region (Fig. 2) is not observed in our
structure. It appears that the original binding site was indeed an
artifact resulting from the induced conformational changes in
the hF loop region caused by three of the four mutations in
14-1B. The effects of halide salts on stability were studied in the
work published by Stout et al. (12), and a preferential stabilization was observed, with fluorine exhibiting the greatest effect
followed by chlorine, bromine, and iodine, respectively. These
studies were performed at a single time point following incubation of PAI-1 at either 37 °C or room temperature in a 150 mM
halide concentration. Our studies comparing chlorine, bromine, and fluorine effects on stability, extended to include
both wild type and W175F PAI-1, measured half-lives by
taking measurements over an extended time frame rather
than titrating tPA with PAI-1 at a single incubation time
point. Nonetheless, our studies do not show any significant
differences at the 150 mM concentration. Instead, pronounced differences in half-lives are observed at a 1.0 M
sodium halide concentration, with chloride clearly giving the
highest degree of stabilization of PAI-1. The reason for the
differing results is not clear. We note that the halide salts had
effects on the amidolytic activity of tPA and that controls for
these effects were required for an accurate half-life determination for PAI-1.
Even though the crystals were grown at salt concentrations above those observed in vivo, it is likely that chloridebinding site will be observed under in vivo conditions. As
seen in Fig. 4B, the chloride-binding pocket is disrupted in
the latent form of PAI-1 because of rearrangements caused
by the movement of secondary structural elements when
␤-sheet A expands upon RCL insertion. The former strand
s1C, extracted from ␤-sheet C during latency transition, now
stretches through the gate region as an extended loop precluding Cl⫺ binding. In summary, the new data provide a
plausible and simple explanation for the stabilizing effect of
salt as reviewed by De Taeye et al. (4). Our data support the
proposed mechanism of chloride stabilization (12) but add a
crucial correction of the actual location of the chloride-binding site to a location more directly linked to the observed
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retardation of latency transition. Furthermore, comparison
of latency transition with other halide salts demonstrated a
specific chloride effect. As the halide ion radii decreasing
from fluorine to iodine, it appears that Cl⫺ must be the optimal size to bind with highest affinity to the site. Because
chloride is the most abundant anionic ion under physiological conditions, this seems reasonable and suggests that this
chloride site has a relevant physiological function.
The Divalent Metal Sites—The fact that two divalent cation
sites are found in the crystal structure (Fig. 3) was surprising
because no metal ions were added intentionally to the crystallization drops. Thus, the metals appear to associate with the
protein either during purification or from trace elements present in the high salt concentration crystal conditions. It is debatable whether one or both of the metal sites are opportunistic,
because they are present only at the dimer interface of the
asymmetric unit. It thus remains an open question at which
stage the metal ions are bound. The Zn2⫹ site at the N terminus of molecule chain A provides a plausible explanation for
the fact that monomeric PAI-1 can be purified by divalent
cation affinity chromatography without the use of specific
protein tags (34). It is feasible that the metal chelating carboxyl groups of a metal-chelating Sepharose resin replace
the metal ion coordination of Glu212 in chain A (Fig. 3),
thereby mediating binding of PAI-1 through the two N-terminal histidine residues. It should be noted that adding submicromolar concentrations of either divalent zinc or copper
ions to the crystallization drops caused immediate precipitation, supporting a specific interaction of the metals with
PAI-1. This specific metal binding that leads to a conformational change may be relevant to recently published work
that shows a destabilization of the active conformation of
PAI-1 by copper, nickel, or cobalt and metal effects that are
modulated by vitronectin binding to PAI-1 (32, 33).
Conclusion—The initial and final structures of latency transition are now well described by our x-ray crystal structure of
the metastable active PAI-1 W175F and the latent wild type
PAI-1 structure (PDB 1LJ5). This structure for W175F reveals
differences in secondary structural elements in the breach
region and the region involving Helix F and the loop connecting to s3A in the underlying central ␤-sheet. Thus, our
present structure of W175F PAI-1 has revealed important
differences from the 14-1B structure in the very region that
houses three of the four mutations that appear to lead to the
thermostability of the 14-1B form. Furthermore, the change
in structure is found near the flexible joint region that constitutes the binding site for the somatomedin B domain from
vitronectin, a cofactor that regulates the novel latency transition of PAI-1. A change in such a key region for PAI-1
function substantiates the need for a structure that more
closely represents the active metastable form of PAI-1.
Clearly, the movement of individual residues and individual
secondary structural elements during the latency transition
still remains to be established. With these new insights, the
structure of W175F PAI-1 provides an improved and
updated model of active PAI-1 that will better guide mapping of interaction surfaces, molecular mechanics, and in
silico modeling.
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